After World-Leading COVID-19 Vaccine Roll-Out, UK Looks To Next Phase
But Under Pressure To Help Poorer Nations
Executive Summary
The UK’s purchase of 60 million extra Pfizer/BioNTech doses, plus bets on Novavax and Valneva and others gives it a buffer against new variants – so when will it pledge to donate to more needy nations?
You may also be interested in...
US COVID Vaccine Patent Waiver Is Big, Symbolic Blow For Pharma, But The Fight Is Just Beginning
Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It is also not clear whether it is an ominous sign for other industry battles in the US, including the drug pricing debate.
Leap Therapeutics And MacroGenics Among Early Winners And Losers At ESMO
Two companies looking to challenge Merck’s Keytruda with new combinations have had contrasting reactions from investors
Moderna Unveils COVID-19 Booster Data As Pfizer Goes Before Skeptical Regulators
Moderna is hot on the heels of Pfizer with booster data for its COVID-19 vaccine, and could benefit from its rival being first to face potential skepticism from the US FDA over booster data for its vaccine.